<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 25 Feb 2025 02:46:30 +0000</lastbuilddate>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Artificial intelligence applied to electrocardiogram to rule out acute myocardial infarction: the ROMIAE multicentre study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39992309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this multicentre prospective study, the AI-ECG demonstrated diagnostic accuracy and predictive power for AMI and 30 day MACE, which was similar to or better than that of traditional risk stratification methods and ED physicians.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 24:ehaf004. doi: 10.1093/eurheartj/ehaf004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Emerging evidence supports artificial intelligence-enhanced electrocardiogram (AI-ECG) for detecting acute myocardial infarction (AMI), but real-world validation is needed. The aim of this study was to evaluate the performance of AI-ECG in detecting AMI in the emergency department (ED).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Rule-Out acute Myocardial Infarction using Artificial intelligence Electrocardiogram analysis (ROMIAE) study is a prospective cohort study conducted in the Republic of Korea from March 2022 to October 2023, involving 18 university-level teaching hospitals. Adult patients presenting to the ED within 24 h of symptom onset concerning for AMI were assessed. Exposure included AI-ECG score, HEART score, GRACE 2.0 score, high-sensitivity troponin level, and Physician AMI score. The primary outcome was diagnosis of AMI during index admission, and the secondary outcome was 30 day major adverse cardiovascular event (MACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population comprised 8493 adults, of whom 1586 (18.6%) were diagnosed with AMI. The area under the receiver operating characteristic curve for AI-ECG was 0.878 (95% CI, 0.868-0.888), comparable with the HEART score (0.877; 95% CI, 0.869-0.886) and superior to the GRACE 2.0 score, high-sensitivity troponin level, and Physician AMI score. For predicting 30 day MACE, AI-ECG (area under the receiver operating characteristic, 0.866; 95% CI, 0.856-0.877) performed comparably with the HEART score (0.858; 95% CI, 0.848-0.868). The integration of the AI-ECG improved risk stratification and AMI discrimination, with a net reclassification improvement of 19.6% (95% CI, 17.38-21.89) and a C-index of 0.926 (95% CI, 0.919-0.933), compared with the HEART score alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this multicentre prospective study, the AI-ECG demonstrated diagnostic accuracy and predictive power for AMI and 30 day MACE, which was similar to or better than that of traditional risk stratification methods and ED physicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39992309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39992309</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf004>10.1093/eurheartj/ehaf004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39992309</guid>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Min Sung Lee</dc:creator>
<dc:creator>Tae Gun Shin</dc:creator>
<dc:creator>Youngjoo Lee</dc:creator>
<dc:creator>Dong Hoon Kim</dc:creator>
<dc:creator>Sung Hyuk Choi</dc:creator>
<dc:creator>Hanjin Cho</dc:creator>
<dc:creator>Mi Jin Lee</dc:creator>
<dc:creator>Ki Young Jeong</dc:creator>
<dc:creator>Won Young Kim</dc:creator>
<dc:creator>Young Gi Min</dc:creator>
<dc:creator>Chul Han</dc:creator>
<dc:creator>Jae Chol Yoon</dc:creator>
<dc:creator>Eujene Jung</dc:creator>
<dc:creator>Woo Jeong Kim</dc:creator>
<dc:creator>Chiwon Ahn</dc:creator>
<dc:creator>Jeong Yeol Seo</dc:creator>
<dc:creator>Tae Ho Lim</dc:creator>
<dc:creator>Jae Seong Kim</dc:creator>
<dc:creator>Jeff Choi</dc:creator>
<dc:creator>Joon-Myoung Kwon</dc:creator>
<dc:creator>Kyuseok Kim</dc:creator>
<dc:creator>ROMIAE study group</dc:creator>
<dc:date>2025-02-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence applied to electrocardiogram to rule out acute myocardial infarction: the ROMIAE multicentre study</dc:title>
<dc:identifier>pmid:39992309</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf004</dc:identifier>
</item>
<item>
<title>Sex-specific pathways from vascular ageing to cardiac damage: unfavourable pulse pressure trajectories induce atrial fibrillation in women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39991783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 24:ehaf039. doi: 10.1093/eurheartj/ehaf039. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39991783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39991783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf039>10.1093/eurheartj/ehaf039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39991783</guid>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Rosa Maria Bruno</dc:creator>
<dc:creator>Emmanuelle Vidal Petiot</dc:creator>
<dc:date>2025-02-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-specific pathways from vascular ageing to cardiac damage: unfavourable pulse pressure trajectories induce atrial fibrillation in women</dc:title>
<dc:identifier>pmid:39991783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf039</dc:identifier>
</item>
<item>
<title>Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39989365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients undergoing left ventricular catheter ablation procedures, a transseptal approach reduced the risk of acute brain lesions by nearly half compared with a retrograde aortic approach without sacrificing safety or efficacy. Given a likely embolic pathogenesis, the brain magnetic resonance imaging findings may reflect a propensity to other organ damage; these findings may extend to other procedures requiring left ventricular entry.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 24. doi: 10.1161/CIRCULATIONAHA.124.071352. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Catheter ablation of ventricular arrhythmias, one of the most rapidly growing procedures in cardiac electrophysiology, is associated with magnetic resonance imaging-detected brain lesions in more than half of cases. Although a retrograde aortic approach is conventional, modern tools enable entry through a transseptal approach that may avoid embolization of debris from the arterial system. We sought to test the hypothesis that a transseptal puncture would mitigate brain injury compared with a retrograde aortic approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The TRAVERSE trial (Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli) was a multicenter randomized controlled comparative effectiveness trial. Patients with left ventricular arrhythmias undergoing catheter ablation procedures were randomly assigned to a transseptal puncture approach compared (1:1) with a retrograde aortic approach. The primary outcome was the presence of an acute brain lesion detected by magnetic resonance imaging. Secondary outcomes included clinically manifest complications, procedural efficacy, and 6-month neurocognitive assessments.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 62 patients randomly assigned to a retrograde aortic approach with postoperative brain magnetic resonance imaging, 28 (45%) exhibited an acute brain lesion compared with 19 of the 69 (28%) of those randomized to a transseptal puncture (<i>P</i>=0.036). No differences in clinically manifest complications or procedural efficacy were observed. More patients in the retrograde aortic arm were categorized as having a high likelihood of cognitive impairment at 6 months (33% compared with 19% of those in the transseptal arm), but substantial loss to follow-up was present.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients undergoing left ventricular catheter ablation procedures, a transseptal approach reduced the risk of acute brain lesions by nearly half compared with a retrograde aortic approach without sacrificing safety or efficacy. Given a likely embolic pathogenesis, the brain magnetic resonance imaging findings may reflect a propensity to other organ damage; these findings may extend to other procedures requiring left ventricular entry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03946072.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39989365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39989365</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071352>10.1161/CIRCULATIONAHA.124.071352</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39989365</guid>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Roderick Tung</dc:creator>
<dc:creator>Edward P Gerstenfeld</dc:creator>
<dc:creator>Trisha F Hue</dc:creator>
<dc:creator>Feng Lin</dc:creator>
<dc:creator>Jing Cheng</dc:creator>
<dc:creator>J Peter Weiss</dc:creator>
<dc:creator>Wendy S Tzou</dc:creator>
<dc:creator>Henry Hsia</dc:creator>
<dc:creator>Ashkan Ehdaie</dc:creator>
<dc:creator>Daniel H Cooper</dc:creator>
<dc:creator>T Jared Bunch</dc:creator>
<dc:creator>Jeffrey Arkles</dc:creator>
<dc:creator>Babak Nazer</dc:creator>
<dc:creator>Adam Lee</dc:creator>
<dc:creator>Alexios Hadjis</dc:creator>
<dc:creator>Duy T Nguyen</dc:creator>
<dc:creator>Mihail G Chelu</dc:creator>
<dc:creator>Joshua Moss</dc:creator>
<dc:creator>Jonathan C Hsu</dc:creator>
<dc:creator>Miguel Valderrábano</dc:creator>
<dc:creator>Prashant D Bhave</dc:creator>
<dc:creator>Andrew D Beaser</dc:creator>
<dc:creator>Arvindh Kanagasundram</dc:creator>
<dc:creator>Oussama Wazni</dc:creator>
<dc:creator>Jason Bradfield</dc:creator>
<dc:creator>Grace Wall</dc:creator>
<dc:creator>Kathleen Chang</dc:creator>
<dc:creator>Michelle Yang</dc:creator>
<dc:creator>Gabrielle Montenegro</dc:creator>
<dc:creator>Sabrina Jarrott</dc:creator>
<dc:creator>Joel H Kramer</dc:creator>
<dc:creator>Anthony S Kim</dc:creator>
<dc:creator>Yvonne M Morris</dc:creator>
<dc:creator>William P Dillon</dc:creator>
<dc:date>2025-02-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial</dc:title>
<dc:identifier>pmid:39989365</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071352</dc:identifier>
</item>
<item>
<title>Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39989358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results show that ALDH1A1 is downregulated in calcified valves, hence promoting VIC transition into an osteoblastic phenotype. Retinoic acid receptor alpha agonists, including all-trans retinoic acid through a drug repositioning strategy, represent a promising and innovative pharmacological approach to prevent calcification of native aortic valves and BPV.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 24. doi: 10.1161/CIRCULATIONAHA.124.071954. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: To date, the only effective treatment of severe aortic stenosis is valve replacement. With the introduction of transcatheter aortic valve replacement and extending indications to younger patients, the use of bioprosthetic valves (BPVs) has considerably increased. The main inconvenience of BPVs is their limited durability because of mechanisms similar as the fibro-calcifying processes observed in native aortic stenosis. One of the major gaps of the field is to identify therapeutic targets to prevent or slow the fibro-calcifying process leading to severe and symptomatic aortic stenosis. The aim was to identify new targets for anticalcification drugs to prevent aortic and BPV calcification using an unbiased translational approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Explanted valves were collected from patients and organ donor hearts. A comparative transcriptomic analysis was performed on valvular interstitial cells (VIC) obtained from calcified (bicuspid and tricuspid) versus control valves. The mechanisms and consequences of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) downregulation were analyzed in VIC cultures from control human aortic valves. ALDH1A1 was inhibited or silenced and its impact on osteogenic marker expression and calcification processes assessed in VIC. The effect of all-trans retinoic acid on calcification was tested on human VIC cultures and on 2 animal models: the model of subcutaneous implantation of bovine pericardium in rats and the model of xenograft aortic valve replacement in juvenile sheep.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Transcriptome analysis of human VIC identified ALDHA1 as the most downregulated gene in VIC from calcified versus control valves. In human VIC, ALDH1A1 expression is downregulated by TGF-β1 in a SMAD2/3-dependent manner. ALDH1A1 inhibition promotes an osteoblast-like VIC phenotype and increases calcium deposition through inhibition of retinoic acid receptor alpha signaling. Conversely, VIC treatment with retinoids decreases calcium deposition and attenuates VIC osteoblast activity. Last, all-trans retinoic acid inhibits calcification development of aortic BPV in both in vivo models and improves aortic valve echocardiographic parameters in the xenograft sheep model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results show that ALDH1A1 is downregulated in calcified valves, hence promoting VIC transition into an osteoblastic phenotype. Retinoic acid receptor alpha agonists, including all-trans retinoic acid through a drug repositioning strategy, represent a promising and innovative pharmacological approach to prevent calcification of native aortic valves and BPV.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39989358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39989358</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071954>10.1161/CIRCULATIONAHA.124.071954</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39989358</guid>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Mickael Rosa</dc:creator>
<dc:creator>Annabelle Dupont</dc:creator>
<dc:creator>David M Smadja</dc:creator>
<dc:creator>Jérôme Soquet</dc:creator>
<dc:creator>Johan Abdoul</dc:creator>
<dc:creator>Thibault Pamart</dc:creator>
<dc:creator>Flavien Vincent</dc:creator>
<dc:creator>Christina Le Tanno</dc:creator>
<dc:creator>Eloise Borowczac</dc:creator>
<dc:creator>Timothée Bigot</dc:creator>
<dc:creator>Alexandre Ung</dc:creator>
<dc:creator>Bertrand Vaast</dc:creator>
<dc:creator>Mélanie Daniel</dc:creator>
<dc:creator>Ramadan Jashari</dc:creator>
<dc:creator>Frédéric Mouquet</dc:creator>
<dc:creator>Cedric Delhaye</dc:creator>
<dc:creator>Yoann Sottejeau</dc:creator>
<dc:creator>Jeanne Rancic</dc:creator>
<dc:creator>Delphine Corseaux</dc:creator>
<dc:creator>Francis Juthier</dc:creator>
<dc:creator>Bart Staels</dc:creator>
<dc:creator>Sophie Susen</dc:creator>
<dc:creator>Eric Van Belle</dc:creator>
<dc:date>2025-02-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning</dc:title>
<dc:identifier>pmid:39989358</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071954</dc:identifier>
</item>
<item>
<title>Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39989354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 24. doi: 10.1161/CIRCULATIONAHA.123.066523. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >;50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS (https://www.clinicaltrials.gov; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS (https://www.clinicaltrials.gov; Unique identifier: NCT02481258).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02481258.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39989354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39989354</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066523>10.1161/CIRCULATIONAHA.123.066523</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39989354</guid>
<pubDate>Mon, 24 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Bin Zhang</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:creator>Hartzell V Schaff</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Carolyn M Roos</dc:creator>
<dc:creator>Michael A Hagler</dc:creator>
<dc:creator>Heyu Zhang</dc:creator>
<dc:creator>Grace Casaclang-Verzosa</dc:creator>
<dc:creator>Runqing Huang</dc:creator>
<dc:creator>Anna Bartoo</dc:creator>
<dc:creator>Sushant Ranadive</dc:creator>
<dc:creator>Michael J Joyner</dc:creator>
<dc:creator>Sorin Pislaru</dc:creator>
<dc:creator>Vuyisile Nkomo</dc:creator>
<dc:creator>Walter K Kremers</dc:creator>
<dc:creator>Philip Araoz</dc:creator>
<dc:creator>Gurpreet Singh</dc:creator>
<dc:creator>Michael A Walters</dc:creator>
<dc:creator>Jon Hawkinson</dc:creator>
<dc:creator>Kevin Y Cunningham</dc:creator>
<dc:creator>Jaeyun Sung</dc:creator>
<dc:creator>Brandon Dunagan</dc:creator>
<dc:creator>Ze Yi</dc:creator>
<dc:creator>Jordan D Miller</dc:creator>
<dc:date>2025-02-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy</dc:title>
<dc:identifier>pmid:39989354</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066523</dc:identifier>
</item>
<item>
<title>Rift Valley fever virus coordinates the assembly of a programmable E3 ligase to promote viral replication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39987918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 22:S0092-8674(25)00193-X. doi: 10.1016/j.cell.2025.02.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39987918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39987918</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.008>10.1016/j.cell.2025.02.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39987918</guid>
<pubDate>Sun, 23 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Huiling Li</dc:creator>
<dc:creator>Yulan Zhang</dc:creator>
<dc:creator>Guibo Rao</dc:creator>
<dc:creator>Chongtao Zhang</dc:creator>
<dc:creator>Zhenqiong Guan</dc:creator>
<dc:creator>Ziyan Huang</dc:creator>
<dc:creator>Shufen Li</dc:creator>
<dc:creator>Pierre-Yves Lozach</dc:creator>
<dc:creator>Sheng Cao</dc:creator>
<dc:creator>Ke Peng</dc:creator>
<dc:date>2025-02-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Rift Valley fever virus coordinates the assembly of a programmable E3 ligase to promote viral replication</dc:title>
<dc:identifier>pmid:39987918</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.008</dc:identifier>
</item>
<item>
<title>Salt sensitivity of blood pressure: mechanisms and sex-specific differences</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39984695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Salt sensitivity of blood pressure (SSBP) is an independent risk factor for cardiovascular disease in individuals with or without hypertension. However, the mechanisms and management of SSBP remain unclear, mainly because the diagnosis of this condition relies on salt loading-depletion protocols that are not feasible in the clinic. The prevalence of hypertension is lower in premenopausal women than in men, but this sex-specific difference is reversed after menopause. Whether excessive SSBP in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 21. doi: 10.1038/s41569-025-01135-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Salt sensitivity of blood pressure (SSBP) is an independent risk factor for cardiovascular disease in individuals with or without hypertension. However, the mechanisms and management of SSBP remain unclear, mainly because the diagnosis of this condition relies on salt loading-depletion protocols that are not feasible in the clinic. The prevalence of hypertension is lower in premenopausal women than in men, but this sex-specific difference is reversed after menopause. Whether excessive SSBP in women at any age contributes to this reversal is unknown, but many clinical studies that have rigorously assessed for SSBP using salt loading-depletion protocols have confirmed that SSBP is more prevalent in women than in men, including during premenopausal age. In this Review, we discuss sex-specific mechanisms of SSBP. We describe sex-related differences in renal transporters, hypertensive pregnancy, SSBP in autoimmune disorders and mitogen-activated protein kinase signalling pathways, and highlight limitations and lessons learned from Dahl salt-sensitive rat models.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39984695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39984695</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01135-0>10.1038/s41569-025-01135-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39984695</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sepiso K Masenga</dc:creator>
<dc:creator>Nelson Wandira</dc:creator>
<dc:creator>Giuliana Cattivelli-Murdoch</dc:creator>
<dc:creator>Mohammad Saleem</dc:creator>
<dc:creator>Heather Beasley</dc:creator>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Lale A Ertuglu</dc:creator>
<dc:creator>Naome Mwesigwa</dc:creator>
<dc:creator>Thomas R Kleyman</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Salt sensitivity of blood pressure: mechanisms and sex-specific differences</dc:title>
<dc:identifier>pmid:39984695</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01135-0</dc:identifier>
</item>
<item>
<title>A nucleosome switch primes hepatitis B virus infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Chronic hepatitis B virus (HBV) infection is an incurable pathogen responsible for causing liver disease and hepatocellular carcinoma. During the genesis of infection, HBV establishes an independent minichromosome consisting of the viral covalently closed circular DNA (cccDNA) genome and host histones. The viral X gene must be expressed immediately upon infection to induce degradation of the host silencing factor, the Smc5/6 complex. However, the relationship between cccDNA chromatinization and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 16:S0092-8674(25)00102-3. doi: 10.1016/j.cell.2025.01.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic hepatitis B virus (HBV) infection is an incurable pathogen responsible for causing liver disease and hepatocellular carcinoma. During the genesis of infection, HBV establishes an independent minichromosome consisting of the viral covalently closed circular DNA (cccDNA) genome and host histones. The viral X gene must be expressed immediately upon infection to induce degradation of the host silencing factor, the Smc5/6 complex. However, the relationship between cccDNA chromatinization and X gene transcription remains poorly understood. By establishing a reconstituted viral minichromosome platform, we found that nucleosome occupancy in cccDNA regulates X transcription. We corroborated these findings in situ and further showed that the chromatin-destabilizing molecule CBL137 inhibits full-length X transcription and HBV infection in primary human hepatocytes. Our results shed light on a long-standing paradox and represent a potential therapeutic approach for the treatment of chronic HBV infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39983728</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.033>10.1016/j.cell.2025.01.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983728</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nicholas A Prescott</dc:creator>
<dc:creator>Tracy Biaco</dc:creator>
<dc:creator>Andrés Mansisidor</dc:creator>
<dc:creator>Yaron Bram</dc:creator>
<dc:creator>Justin Rendleman</dc:creator>
<dc:creator>Sarah C Faulkner</dc:creator>
<dc:creator>Abigail A Lemmon</dc:creator>
<dc:creator>Christine Lim</dc:creator>
<dc:creator>Rachel Tiersky</dc:creator>
<dc:creator>Eralda Salataj</dc:creator>
<dc:creator>Liliana Garcia-Martinez</dc:creator>
<dc:creator>Rodrigo L Borges</dc:creator>
<dc:creator>Lluis Morey</dc:creator>
<dc:creator>Pierre-Jacques Hamard</dc:creator>
<dc:creator>Richard P Koche</dc:creator>
<dc:creator>Viviana I Risca</dc:creator>
<dc:creator>Robert E Schwartz</dc:creator>
<dc:creator>Yael David</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A nucleosome switch primes hepatitis B virus infection</dc:title>
<dc:identifier>pmid:39983728</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.033</dc:identifier>
</item>
<item>
<title>Plasmodesmata act as unconventional membrane contact sites regulating intercellular molecular exchange in plants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Membrane contact sites (MCSs) are fundamental for intracellular communication, but their role in intercellular communication remains unexplored. We show that in plants, plasmodesmata communication bridges function as atypical endoplasmic reticulum (ER)-plasma membrane (PM) tubular MCSs, operating at cell-cell interfaces. Similar to other MCSs, ER-PM apposition is controlled by a protein-lipid tethering complex, but uniquely, this serves intercellular communication. Combining high-resolution...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):958-977.e23. doi: 10.1016/j.cell.2024.11.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Membrane contact sites (MCSs) are fundamental for intracellular communication, but their role in intercellular communication remains unexplored. We show that in plants, plasmodesmata communication bridges function as atypical endoplasmic reticulum (ER)-plasma membrane (PM) tubular MCSs, operating at cell-cell interfaces. Similar to other MCSs, ER-PM apposition is controlled by a protein-lipid tethering complex, but uniquely, this serves intercellular communication. Combining high-resolution microscopy, molecular dynamics, and pharmacological and genetic approaches, we show that cell-cell trafficking is modulated through the combined action of multiple C2 domains transmembrane domain proteins (MCTPs) 3, 4, and 6 ER-PM tethers and phosphatidylinositol-4-phosphate (PI4P) lipid. Graded PI4P amounts regulate MCTP docking to the PM, their plasmodesmata localization, and cell-cell permeability. SAC7, an ER-localized PI4P-phosphatase, regulates MCTP4 accumulation at plasmodesmata and modulates cell-cell trafficking capacity in a cell-type-specific manner. Our findings expand MCS functions in information transmission from intracellular to intercellular cellular activities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39983675</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.034>10.1016/j.cell.2024.11.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983675</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jessica Pérez-Sancho</dc:creator>
<dc:creator>Marija Smokvarska</dc:creator>
<dc:creator>Gwennogan Dubois</dc:creator>
<dc:creator>Marie Glavier</dc:creator>
<dc:creator>Sujith Sritharan</dc:creator>
<dc:creator>Tatiana S Moraes</dc:creator>
<dc:creator>Hortense Moreau</dc:creator>
<dc:creator>Victor Dietrich</dc:creator>
<dc:creator>Matthieu P Platre</dc:creator>
<dc:creator>Andrea Paterlini</dc:creator>
<dc:creator>Ziqiang P Li</dc:creator>
<dc:creator>Laetitia Fouillen</dc:creator>
<dc:creator>Magali S Grison</dc:creator>
<dc:creator>Pepe Cana-Quijada</dc:creator>
<dc:creator>Françoise Immel</dc:creator>
<dc:creator>Valerie Wattelet</dc:creator>
<dc:creator>Mathieu Ducros</dc:creator>
<dc:creator>Lysiane Brocard</dc:creator>
<dc:creator>Clément Chambaud</dc:creator>
<dc:creator>Yongming Luo</dc:creator>
<dc:creator>Priya Ramakrishna</dc:creator>
<dc:creator>Vincent Bayle</dc:creator>
<dc:creator>Linnka Lefebvre-Legendre</dc:creator>
<dc:creator>Stéphane Claverol</dc:creator>
<dc:creator>Matej Zabrady</dc:creator>
<dc:creator>Pascal G P Martin</dc:creator>
<dc:creator>Wolfgang Busch</dc:creator>
<dc:creator>Marie Barberon</dc:creator>
<dc:creator>Jens Tilsner</dc:creator>
<dc:creator>Yrjö Helariutta</dc:creator>
<dc:creator>Eugenia Russinova</dc:creator>
<dc:creator>Antoine Taly</dc:creator>
<dc:creator>Yvon Jaillais</dc:creator>
<dc:creator>Emmanuelle M Bayer</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Plasmodesmata act as unconventional membrane contact sites regulating intercellular molecular exchange in plants</dc:title>
<dc:identifier>pmid:39983675</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.034</dc:identifier>
</item>
<item>
<title>Advances in the study and treatment of genetic cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and arrhythmogenic cardiomyopathy (ACM), with right, left, or biventricular involvement and arrhythmias out of proportion to systolic dysfunction. Genetic discoveries of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):901-918. doi: 10.1016/j.cell.2025.01.011.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and arrhythmogenic cardiomyopathy (ACM), with right, left, or biventricular involvement and arrhythmias out of proportion to systolic dysfunction. Genetic discoveries of the molecular basis of disease are paving the way for greater precision in diagnosis and management and revealing mechanisms that account for distinguishing clinical features. This deeper understanding has propelled the development of new treatments for cardiomyopathies: disease-specific, mechanistically based medicines that counteract pathophysiology, and emergent gene therapies that aim to intercept disease progression and restore cardiac physiology. Together, these discoveries have advanced fundamental insights into cardiac biology and herald a new era for patients with cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39983674</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.011>10.1016/j.cell.2025.01.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983674</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Eric D Adler</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Advances in the study and treatment of genetic cardiomyopathies</dc:title>
<dc:identifier>pmid:39983674</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.011</dc:identifier>
</item>
<item>
<title>Cellular responses to RNA damage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>RNA plays a central role in protein biosynthesis and performs diverse regulatory and catalytic functions, making it essential for all processes of life. Like DNA, RNA is constantly subjected to damage from endogenous and environmental sources. However, while the DNA damage response has been extensively studied, it was long assumed that RNA lesions are relatively inconsequential due to the transient nature of most RNA molecules. Here, we review recent studies that challenge this view by revealing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):885-900. doi: 10.1016/j.cell.2025.01.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RNA plays a central role in protein biosynthesis and performs diverse regulatory and catalytic functions, making it essential for all processes of life. Like DNA, RNA is constantly subjected to damage from endogenous and environmental sources. However, while the DNA damage response has been extensively studied, it was long assumed that RNA lesions are relatively inconsequential due to the transient nature of most RNA molecules. Here, we review recent studies that challenge this view by revealing complex RNA damage responses that determine survival when cells are exposed to nucleic acid-damaging agents and promote the resolution of RNA lesions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39983673</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.005>10.1016/j.cell.2025.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983673</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacqueline Cordes</dc:creator>
<dc:creator>Shubo Zhao</dc:creator>
<dc:creator>Carla M Engel</dc:creator>
<dc:creator>Julian Stingele</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cellular responses to RNA damage</dc:title>
<dc:identifier>pmid:39983673</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.005</dc:identifier>
</item>
<item>
<title>Solute carriers: The gatekeepers of metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Solute carrier (SLC) proteins play critical roles in maintaining cellular and organismal homeostasis by transporting small molecules and ions. Despite a growing body of research over the past decade, physiological substrates and functions of many SLCs remain elusive. This perspective outlines key challenges in studying SLC biology and proposes an evidence-based framework for defining SLC substrates. To accelerate the deorphanization process, we explore systematic technologies, including human...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):869-884. doi: 10.1016/j.cell.2025.01.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Solute carrier (SLC) proteins play critical roles in maintaining cellular and organismal homeostasis by transporting small molecules and ions. Despite a growing body of research over the past decade, physiological substrates and functions of many SLCs remain elusive. This perspective outlines key challenges in studying SLC biology and proposes an evidence-based framework for defining SLC substrates. To accelerate the deorphanization process, we explore systematic technologies, including human genetics, biochemistry, and computational and structural approaches. Finally, we suggest directions to better understand SLC functions beyond substrate identification in physiology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39983672</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.015>10.1016/j.cell.2025.01.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983672</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Artem Khan</dc:creator>
<dc:creator>Yuyang Liu</dc:creator>
<dc:creator>Mark Gad</dc:creator>
<dc:creator>Timothy C Kenny</dc:creator>
<dc:creator>Kıvanç Birsoy</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Solute carriers: The gatekeepers of metabolism</dc:title>
<dc:identifier>pmid:39983672</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.015</dc:identifier>
</item>
<item>
<title>Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39982387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf079. doi: 10.1093/eurheartj/ehaf079. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39982387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39982387</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf079>10.1093/eurheartj/ehaf079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39982387</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)</dc:title>
<dc:identifier>pmid:39982387</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf079</dc:identifier>
</item>
<item>
<title>Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In ACS patients, TiNOS was associated with similar rates of MACE and TLR as compared with DES but significantly lower rates of CD, MI, and stent thrombosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf098. doi: 10.1093/eurheartj/ehaf098. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In acute coronary syndromes (ACS), vascular healing at the site of implantation of drug-eluting stents (DES) can be delayed. Titanium-nitride-oxide-coated stents (TiNOS) demonstrate faster strut coverage without the excessive intimal hyperplasia observed with bare metal stents. The 5-year outcomes of patients presenting with ACS, randomized to receive either TiNOS or DES, were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A systematic review and individual participant data meta-analysis of trials comparing TiNOS with DES for the treatment of ACS was conducted (PROSPERO: CRD42024514342). The primary endpoint was major adverse cardiac events (MACE) at 5 years, a composite of cardiac death (CD), myocardial infarction (MI), and ischaemia-driven target lesion revascularization (TLR). Pre-specified secondary endpoints included CD, MI, TLR, and stent thrombosis. Data were pooled using a mixed-effects Cox regression model with random slope and stratified baseline hazards.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patient-level data (n = 2743) were obtained from three randomized controlled trials (TiNOS: n = 1620 vs. DES: n = 1123). After a median follow-up of 4.93 years, there was no significant difference in the primary endpoint between TiNOS and DES (12.6% vs. 16.2%; hazard ratio [HR] .82, 95% confidence interval [CI] .67-1.00, P = .051), mainly due to a similar rate of TLR (8.0% vs. 8.1%; HR 1.05, 95% CI .80-1.38, P = .733). However, TiNOS was associated with significantly lower rates of CD (1.5% vs. 3.7%; HR .46, 95% CI .26-.81, P = .007), MI (5.2% vs. 9.6%; HR .56, 95% CI .42-.75, P &lt; .001), and stent thrombosis (1.1% vs. 3.8%; HR .30, 95% CI .17-.53, P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ACS patients, TiNOS was associated with similar rates of MACE and TLR as compared with DES but significantly lower rates of CD, MI, and stent thrombosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39981941</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf098>10.1093/eurheartj/ehaf098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981941</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Thabo Mahendiran</dc:creator>
<dc:creator>Frederic Bouisset</dc:creator>
<dc:creator>Pim Tonino</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Jussi Sia</dc:creator>
<dc:creator>Kari Kervinen</dc:creator>
<dc:creator>Fernando Rivero-Crespo</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Bruno Roza da Costa</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Takuya Mizukami</dc:creator>
<dc:creator>Pasi Karjalainen</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis</dc:title>
<dc:identifier>pmid:39981941</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf098</dc:identifier>
</item>
<item>
<title>Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Brain glymphatic function measured by DTI-ALPS index was impaired in patients with AF, mediates the association between AF and cognitive decline, and was improved after ablation therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf036. doi: 10.1093/eurheartj/ehaf036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: It remains unknown whether the brain glymphatic system, which is driven by the heartbeat-driven pulsation of arteries and is responsible for cerebral waste clearance, is impaired in atrial fibrillation (AF) and mediates cognitive dysfunction related to AF. The aim of this study was to assess brain glymphatic alterations in AF, their role in cognitive function, and whether catheter ablation can improve glymphatic activity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this case-control and prospective before-and-after study, patients with AF and healthy controls (HCs) were enrolled. Participants underwent brain magnetic resonance imaging and a comprehensive neuropsychological battery. Glymphatic activity was quantified by diffusion tensor image analysis along the perivascular space (DTI-ALPS) index. Magnetic resonance imaging was repeated after surgery in patients who underwent ablation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 87 patients with AF and 44 HCs were enrolled. Compared with HCs, patients with AF had a lower ALPS index (P = .016). Nonparoxysmal AF patients showed lower ALPS index than both HCs (P = .002) and paroxysmal AF patients (P = .044). A lower ALPS index was associated with worse scores of Trail Making Test, Digit Symbol Substitution Test, Digit Span Test, and Stroop Colour and Word Test (all P &lt; .05). Mediation analyses revealed that glymphatic activity was a mediator between AF and cognitive decline. Among the 50 patients who underwent ablation therapy, DTI-ALPS index was improved after surgery (P = .015).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Brain glymphatic function measured by DTI-ALPS index was impaired in patients with AF, mediates the association between AF and cognitive decline, and was improved after ablation therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39981927</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf036>10.1093/eurheartj/ehaf036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981927</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jiahuan Guo</dc:creator>
<dc:creator>Zhe Zhang</dc:creator>
<dc:creator>Xu Meng</dc:creator>
<dc:creator>Jing Jing</dc:creator>
<dc:creator>Yiran Hu</dc:creator>
<dc:creator>Yan Yao</dc:creator>
<dc:creator>Ligang Ding</dc:creator>
<dc:creator>Lihui Zheng</dc:creator>
<dc:creator>Xingquan Zhao</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance</dc:title>
<dc:identifier>pmid:39981927</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf036</dc:identifier>
</item>
<item>
<title>Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf002. doi: 10.1093/eurheartj/ehaf002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In randomized clinical trials of patients undergoing percutaneous coronary intervention (PCI) for de novo small-vessel coronary artery disease (SV-CAD), paclitaxel-coated balloon (PCB) angioplasty showed mid-term angiographic or clinical non-inferiority to drug-eluting stent (DES) implantation. Nevertheless, these trials have sample size limitations, and the relative safety and efficacy beyond the first year remain uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ANDROMEDA study was a collaborative, investigator-initiated, individual patient data meta-analysis comparing 3 year clinical outcomes between PCB angioplasty and DES implantation for the treatment of de novo SV-CAD. Multiple electronic databases (PubMed, Scopus, ScienceDirect, and Web of Science) were searched from May 2010 to June 2024 to identify eligible trials. All the following eligibility criteria were required: (i) random allocations of treatments; (ii) patients with SV-CAD; (iii) treatment with PCB or DES; and (iv) clinical follow-up of at least 36 months. The primary and co-primary endpoints were major adverse cardiac events (MACE) and target lesion failure (TLF), respectively. The protocol was registered with PROSPERO (CRD42023479035).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Individual patient data from three randomized trials, including a total of 1154 patients and 1360 lesions, were combined. At 3 years, PCB was associated with a lower risk of MACE compared with DES [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.47-0.96], due to a lower risk of myocardial infarction and target vessel revascularization. This benefit persisted after multivariable adjustment (HR 0.75, 95% CI 0.58-0.96), but did not reach statistical significance in the two-stage analysis (HR 0.67, 95% CI 0.43-1.04). At the landmark analysis, the risk of MACE between groups was consistent over time. At 3 years, TLF was not significantly different between PCB and DES groups. Reconstructed time-to-event information from a fourth trial was included in a sensitivity analysis (1384 patients and 1590 lesions), showing consistent results in terms of TLF (HR 0.87, 95% CI 0.63-1.20). The comparison between PCB and second-generation DES did not reveal significant differences in 3 year TLF (HR 1.03, 95% CI 0.70-1.50).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39981922</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf002>10.1093/eurheartj/ehaf002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981922</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Simone Fezzi</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Gregor Fahrni</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>Antonio Colombo</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Bruno Scheller</dc:creator>
<dc:creator>Raban Jeger</dc:creator>
<dc:creator>Bernardo Cortese</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study</dc:title>
<dc:identifier>pmid:39981922</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf002</dc:identifier>
</item>
<item>
<title>Gene therapy targeting INa to treat life-threatening arrhythmias: beyond proof-of-concept?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehae930. doi: 10.1093/eurheartj/ehae930. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39981909</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae930>10.1093/eurheartj/ehae930</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981909</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Patrick Lugenbiel</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gene therapy targeting INa to treat life-threatening arrhythmias: beyond proof-of-concept?</dc:title>
<dc:identifier>pmid:39981909</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae930</dc:identifier>
</item>
<item>
<title>Taking out the trash: the role of glymphatic function in cognitive function in patients with atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf040. doi: 10.1093/eurheartj/ehaf040. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39981908</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf040>10.1093/eurheartj/ehaf040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981908</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>T Jared Bunch</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Taking out the trash: the role of glymphatic function in cognitive function in patients with atrial fibrillation</dc:title>
<dc:identifier>pmid:39981908</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf040</dc:identifier>
</item>
<item>
<title>The growing relevance of sex-specific risk factors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39980454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21;46(8):673-676. doi: 10.1093/eurheartj/ehaf021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39980454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39980454</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf021>10.1093/eurheartj/ehaf021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39980454</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The growing relevance of sex-specific risk factors</dc:title>
<dc:identifier>pmid:39980454</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf021</dc:identifier>
</item>
<item>
<title>SecY translocon chaperones protein folding during membrane protein insertion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39978345/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>The Sec translocon is vital for guiding membrane protein insertion into lipid bilayers. The insertion and folding processes of membrane proteins are poorly understood. Here, we report cryo-electron microscopy structures of multi-spanning membrane proteins inserting through the SecY channel, the Sec translocon in prokaryotes. The high-resolution structures illustrate how bulky amino acids pass the narrow channel restriction. Comparison of different translocation states reveals that the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 12:S0092-8674(25)00106-0. doi: 10.1016/j.cell.2025.01.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Sec translocon is vital for guiding membrane protein insertion into lipid bilayers. The insertion and folding processes of membrane proteins are poorly understood. Here, we report cryo-electron microscopy structures of multi-spanning membrane proteins inserting through the SecY channel, the Sec translocon in prokaryotes. The high-resolution structures illustrate how bulky amino acids pass the narrow channel restriction. Comparison of different translocation states reveals that the cytoplasmic and extracellular cavities of the channel create distinct environments for promoting the unfolding and folding of transmembrane segments (TMs), respectively. Released substrate TMs are either flexible or stabilized by an unexpected hydrophilic groove between TM3 and TM4 of SecY. Disruption of the groove causes global defects in the folding of the membrane proteome. These findings demonstrate that beyond its role as a passive protein-conducting channel, the SecY translocon actively serves as a chaperone, employing multiple mechanisms to promote membrane protein insertion and folding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39978345/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39978345</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.037>10.1016/j.cell.2025.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39978345</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiaomin Ou</dc:creator>
<dc:creator>Chengying Ma</dc:creator>
<dc:creator>Dongjie Sun</dc:creator>
<dc:creator>Jinkun Xu</dc:creator>
<dc:creator>Yang Wang</dc:creator>
<dc:creator>Xiaofei Wu</dc:creator>
<dc:creator>Dali Wang</dc:creator>
<dc:creator>Song Yang</dc:creator>
<dc:creator>Ning Gao</dc:creator>
<dc:creator>Chen Song</dc:creator>
<dc:creator>Long Li</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SecY translocon chaperones protein folding during membrane protein insertion</dc:title>
<dc:identifier>pmid:39978345</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.037</dc:identifier>
</item>
<item>
<title>Motor and vestibular signals in the visual cortex permit the separation of self versus externally generated visual motion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224214629&amp;v=2.18.0.post9+e462414
      <description>Knowing whether we are moving or something in the world is moving around us is possibly the most critical sensory discrimination we need to perform. How the brain and, in particular, the visual system solves this motion-source separation problem is not known. Here, we find that motor, vestibular, and visual motion signals are used by the mouse primary visual cortex (VISp) to differentially represent the same visual flow information according to whether the head is stationary or experiencing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 14:S0092-8674(25)00101-1. doi: 10.1016/j.cell.2025.01.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Knowing whether we are moving or something in the world is moving around us is possibly the most critical sensory discrimination we need to perform. How the brain and, in particular, the visual system solves this motion-source separation problem is not known. Here, we find that motor, vestibular, and visual motion signals are used by the mouse primary visual cortex (VISp) to differentially represent the same visual flow information according to whether the head is stationary or experiencing passive versus active translation. During locomotion, we find that running suppresses running-congruent translation input and that translation signals dominate VISp activity when running and translation speed become incongruent. This cross-modal interaction between the motor and vestibular systems was found throughout the cortex, indicating that running and translation signals provide a brain-wide egocentric reference frame for computing the internally generated and actual speed of self when moving through and sensing the external world.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224214629&v=2.18.0.post9+e462414">39978344</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.032>10.1016/j.cell.2025.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39978344</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Mateo Vélez-Fort</dc:creator>
<dc:creator>Lee Cossell</dc:creator>
<dc:creator>Laura Porta</dc:creator>
<dc:creator>Claudia Clopath</dc:creator>
<dc:creator>Troy W Margrie</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Motor and vestibular signals in the visual cortex permit the separation of self versus externally generated visual motion</dc:title>
<dc:identifier>pmid:39978344</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.032</dc:identifier>
</item>





























</channel>
</rss>